Why It Matters

The Centers for Medicare & Medicaid Services (CMS) has finalized new regulations governing Medicare's prescription drug price negotiation program, establishing rules for determining which medications qualify for negotiation and how certain drug manufacturers are treated. ​

The rule, published Nov. 9, takes effect Dec. 5. Its provisions will apply beginning with the 2029 round of negotiated Medicare drug prices, with drug selection and negotiations beginning in 2027. The changes could affect pharmaceutical manufacturers whose products become eligible for Medicare price negotiations, including companies developing new formulations of existing medications and manufacturers of drugs used to treat rare diseases.

What the Change Does to Existing Law

The rule establishes federal regulations for the Medicare Drug Price Negotiation Program, which previously operated primarily under agency guidance, and updates regulations governing Medicare's prescription drug benefit. One of the most significant changes concerns how CMS identifies drugs that contain combinations of active ingredients. Under the new policy, certain drug products that share active ingredients but use different formulations to allow alternative methods of administration may be treated together when CMS determines whether they qualify for Medicare price negotiations.

Specifically, when a manufacturer develops a new formulation that combines previously administered drug components and allows delivery through a different route, CMS will consider all dosage forms and strengths of the shared active components the same manufacturer offers when identifying a qualifying drug. The rule also clarifies how CMS calculates the seven-year and 11-year periods used to determine when certain drugs become eligible for negotiation, including medications that previously qualified for an exclusion for drugs treating rare diseases.

Additional provisions establish a formal review process for determining whether generic drugs and biosimilars are genuinely being marketed, which can affect whether their brand-name counterparts remain eligible for negotiation. CMS also finalized temporary protections for certain small biotechnology manufacturers for the 2029 and 2030 negotiation cycles.

What It Means

Pharmaceutical manufacturers whose products could be selected for the 2029 negotiation cycle will need to assess how the new rules apply to their drug portfolios, particularly products that combine existing active ingredients or use alternative methods of administration.

Advertisement

Manufacturers of medications that previously qualified for the rare disease drug exclusion will also face clearer standards governing when their products become eligible for price negotiations. The changes could affect how companies structure new drug formulations, assess when their products become eligible for Medicare negotiation, and prepare for negotiations with the federal government.

Companies producing generic drugs and biosimilars will be subject to the finalized process CMS uses to determine whether those products are genuinely available on the market. Medicare prescription drug plans will also be affected by the updated program regulations.

Who Is Driving the Rule

CMS, an agency within the Department of Health and Human Services, finalized the regulations as part of its implementation of Medicare's authority to negotiate prescription drug prices. For questions about the program, CMS lists Elisabeth Daniel, director of the Division of Policy, as a contact. The agency can be reached at [email protected].

The rulemaking comes amid lobbying by pharmaceutical manufacturers and organizations representing the interests of companies developing treatments for rare diseases.

Daiichi Sankyo Inc. reported $130,000 in first-quarter lobbying expenditures, $380,000 in the second quarter and $370,000 in the third quarter on issues including Medicare drug price negotiations, the ORPHAN Cures Act and intellectual property rights.

Save Rare Treatments Task Force reported $50,000 in first-quarter lobbying expenditures and $40,000 in each of the second and third quarters. Its lobbying focused on ensuring that drugs approved exclusively for rare diseases remain excluded from Medicare price negotiations.

Next Step and the Implementation Timeline

The final rule takes effect Dec. 5, with the new regulations applying to negotiated drug prices beginning in 2029. CMS waived the standard 60-day delay that generally applies to certain major federal rules, citing the need to meet the statutory Feb. 1 deadline for publishing the list of selected drugs and to allow time to process requests from biosimilar manufacturers seeking negotiation delays. The rule is final, and no additional public comment period is open.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article